409 related articles for article (PubMed ID: 19153078)
1. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
Le Floch R; Arnould JF; Vinsonneau C; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Lovering AM
Pathol Biol (Paris); 2010 Apr; 58(2):e27-31. PubMed ID: 19854590
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.
Stalker DJ; Jungbluth GL; Hopkins NK; Batts DH
J Antimicrob Chemother; 2003 May; 51(5):1239-46. PubMed ID: 12668582
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration.
Horcajada JP; Atienza R; Sarasa M; Soy D; Adán A; Mensa J
J Antimicrob Chemother; 2009 Mar; 63(3):550-2. PubMed ID: 19109336
[TBL] [Abstract][Full Text] [Related]
6. Impact of ontogeny on linezolid disposition in neonates and infants.
Kearns GL; Jungbluth GL; Abdel-Rahman SM; Hopkins NK; Welshman IR; Grzebyk RP; Bruss JB; Van Den Anker JN;
Clin Pharmacol Ther; 2003 Nov; 74(5):413-22. PubMed ID: 14586382
[TBL] [Abstract][Full Text] [Related]
7. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
Viaggi B; Paolo AD; Danesi R; Polillo M; Ciofi L; Del Tacca M; Malacarne P
Scand J Infect Dis; 2011 Sep; 43(9):721-7. PubMed ID: 21585240
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E.
Gordi T; Tan LH; Hong C; Hopkins NJ; Francom SF; Slatter JG; Antal EJ
J Clin Pharmacol; 2003 Oct; 43(10):1161-7. PubMed ID: 14517199
[TBL] [Abstract][Full Text] [Related]
9. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
MacGowan AP
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii17-25. PubMed ID: 12730139
[TBL] [Abstract][Full Text] [Related]
11. Linezolid pharmacokinetics in pediatric patients: an overview.
Jungbluth GL; Welshman IR; Hopkins NK
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S153-7. PubMed ID: 14520140
[TBL] [Abstract][Full Text] [Related]
12. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients.
Plock N; Buerger C; Joukhadar C; Kljucar S; Kloft C
Drug Metab Dispos; 2007 Oct; 35(10):1816-23. PubMed ID: 17639029
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
[TBL] [Abstract][Full Text] [Related]
14. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?
Hamilton R; Thai XC; Ameri D; Pai MP
J Antimicrob Chemother; 2013 Mar; 68(3):666-73. PubMed ID: 23160755
[TBL] [Abstract][Full Text] [Related]
15. The effect of food on plasma and tissue concentrations of linezolid after multiple doses.
Islinger F; Dehghanyar P; Sauermann R; Bürger C; Kloft C; Müller M; Joukhadar C
Int J Antimicrob Agents; 2006 Feb; 27(2):108-12. PubMed ID: 16388930
[TBL] [Abstract][Full Text] [Related]
16. Effect of severity of sepsis on tissue concentrations of linezolid.
Thallinger C; Buerger C; Plock N; Kljucar S; Wuenscher S; Sauermann R; Kloft C; Joukhadar C
J Antimicrob Chemother; 2008 Jan; 61(1):173-6. PubMed ID: 17999976
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
Wong SL; Barriere SL; Kitt MM; Goldberg MR
J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659
[TBL] [Abstract][Full Text] [Related]
18. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration.
Meyer B; Kornek GV; Nikfardjam M; Karth GD; Heinz G; Locker GJ; Jaeger W; Thalhammer F
J Antimicrob Chemother; 2005 Jul; 56(1):172-9. PubMed ID: 15905303
[TBL] [Abstract][Full Text] [Related]
20. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
Grunder G; Zysset-Aschmann Y; Vollenweider F; Maier T; Krähenbühl S; Drewe J
Antimicrob Agents Chemother; 2006 Jan; 50(1):68-72. PubMed ID: 16377669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
